Therapeutic management of the first episode of pregnancy-onset TTP in 108 patients
| . | iTTP (n = 52) . | uTTP (n = 27) . | cTTP (n = 29) . | Total (N = 108) . |
|---|---|---|---|---|
| PEX | 50/52 (96.2%) | 19/27 (70.3%) | 16/29 (55.2%) | 85/ 108 (78.7%) |
| FFP infusion (no PEX) | 1/52 (1.9%) | 0/27 (0%) | 11/29 (37.9%) | 12/108 (11.1%) |
| Corticosteroids | 42/52 (80.8%) | 19/27 (70.3%) | 15/29 (51.7%) | 76/108 (70.4%) |
| Rituximab | 29/52 (55.8%) | 1/27 (3.7%) | 3/29 (10.3%) | 33/108 (30.6%) |
| Caplacizumab∗ | 4/52 (7.7%) | 0/27 (0%) | 0/29 (0%) | 4/108 (3.7%) |
| Platelet concentrates | 9/52 (17.3%) | 3/27 (11.1%) | 3/29 (10.3%) | 15/108 (13.9%) |
| Antihypertensive drugs | 1/52 (1.9%) | 5/27 (18.5%) | 6/29 (20.6%) | 12/108 (11.1%) |
| Splenectomy | 1/52 (1.9%) | 0/27 (0%) | 0/29 (0%) | 1/108 (0.9%) |
| Cyclophosphamide | 1/52 (1.9%) | 0/27 (0%) | 0/29 (0%) | 1/108 (0.9%) |
| IV immunoglobulin | 3/52 (5.8%) | 0/27 (0%) | 0/29 (0%) | 3/108 (2.8%) |
| Heparin | 3/52 (5.8%) | 1/27 (3.7%) | 0/29 (0%) | 4/108 (3.7%) |
| Aspirin | 6/52 (11.5%) | 1/27 (3.7%) | 0/29 (0%) | 7/108 (6.5%) |
| . | iTTP (n = 52) . | uTTP (n = 27) . | cTTP (n = 29) . | Total (N = 108) . |
|---|---|---|---|---|
| PEX | 50/52 (96.2%) | 19/27 (70.3%) | 16/29 (55.2%) | 85/ 108 (78.7%) |
| FFP infusion (no PEX) | 1/52 (1.9%) | 0/27 (0%) | 11/29 (37.9%) | 12/108 (11.1%) |
| Corticosteroids | 42/52 (80.8%) | 19/27 (70.3%) | 15/29 (51.7%) | 76/108 (70.4%) |
| Rituximab | 29/52 (55.8%) | 1/27 (3.7%) | 3/29 (10.3%) | 33/108 (30.6%) |
| Caplacizumab∗ | 4/52 (7.7%) | 0/27 (0%) | 0/29 (0%) | 4/108 (3.7%) |
| Platelet concentrates | 9/52 (17.3%) | 3/27 (11.1%) | 3/29 (10.3%) | 15/108 (13.9%) |
| Antihypertensive drugs | 1/52 (1.9%) | 5/27 (18.5%) | 6/29 (20.6%) | 12/108 (11.1%) |
| Splenectomy | 1/52 (1.9%) | 0/27 (0%) | 0/29 (0%) | 1/108 (0.9%) |
| Cyclophosphamide | 1/52 (1.9%) | 0/27 (0%) | 0/29 (0%) | 1/108 (0.9%) |
| IV immunoglobulin | 3/52 (5.8%) | 0/27 (0%) | 0/29 (0%) | 3/108 (2.8%) |
| Heparin | 3/52 (5.8%) | 1/27 (3.7%) | 0/29 (0%) | 4/108 (3.7%) |
| Aspirin | 6/52 (11.5%) | 1/27 (3.7%) | 0/29 (0%) | 7/108 (6.5%) |
The results are presented as number of patients who received the therapeutic options per number of patients (percentage).
FFP, fresh frozen plasma; PEX, plasma exchange.
Caplacizumab was used postpartum.